Cargando…

Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy

BACKGROUND: To assess factors associated with the preferred role of the attending ophthalmologist in the decision-making processes before treating diabetic retinopathy (DR). METHODS: Cross-sectional study of 810 adults attending secondary diabetes care centers (NCT02311504). Diabetes patients were c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marahrens, Lydia, Kern, Raimar, Ziemssen, Tjalf, Fritsche, Andreas, Martus, Peter, Ziemssen, Focke, Roeck, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551005/ https://www.ncbi.nlm.nih.gov/pubmed/28793881 http://dx.doi.org/10.1186/s12886-017-0526-z

Ejemplares similares

Interdisziplinäre Kommunikation: Augenarztbriefe an diabetologische Schwerpunktpraxen (DSP)
por: Stock, Lydia, et al.
Publicado: (2020)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System
por: Kern, Raimar, et al.
Publicado: (2016)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis
por: Böttrich, Niels, et al.
Publicado: (2020)

Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study
por: Haase, Rocco, et al.
Publicado: (2012)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2008)

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
por: Ness, Nils-Henning, et al.
Publicado: (2020)

Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures
por: Paucke, Madlen, et al.
Publicado: (2018)

Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study
por: Reimann, Manja, et al.
Publicado: (2013)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

A Digital Patient Portal for Patients With Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2020)

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Morphology of foveal hypoplasia: Hyporeflective zones in the Henle fiber layer of eyes with high-grade foveal hypoplasia
por: Bringmann, Andreas, et al.
Publicado: (2022)

Bevacizumab: Off-label use in ophthalmology
por: Grisanti, Salvatore, et al.
Publicado: (2007)

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
por: Klistorner, Alexander, et al.
Publicado: (2018)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Time-On-Task Effects on Working Memory Gating Processes—A Role of Theta Synchronization and the Norepinephrine System
por: Yu, Shijing, et al.
Publicado: (2022)

Cortisol Awakening Response Is Linked to Disease Course and Progression in Multiple Sclerosis
por: Kern, Simone, et al.
Publicado: (2013)

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)
por: Ziemssen, Tjalf, et al.
Publicado: (2023)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Testing for SARS-CoV-2 seroprevalence: experiences of a tertiary eye centre
por: Ziemssen, Focke, et al.
Publicado: (2021)

Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration
por: Sobolewska, Bianka, et al.
Publicado: (2021)

The importance of collecting structured clinical information on multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Spectral Analysis of Heart Rate Variability: Time Window Matters
por: Li, Kai, et al.
Publicado: (2019)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1nnfr9os01sb26ph2ihbm4rkbj